Petros Pharmaceuticals

Equities

PTPI

US71678J2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
0.6801 ^USD	+4.60%		-1.43%	-51.77%

Apr. 23	Petros, Lemonaid Health Collaborate to Expand Stendra Availability	MT
Apr. 16	Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	MT

Petros Pharmaceuticals, Inc. Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ to the United States

January 24, 2022 at 09:15 am EST

Petros Pharmaceuticals, Inc. announced it has partnered with a leading Contract Development and Manufacturing Organization (CDMO), for commercial production of STENDRA (avanafil) tablets. The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the product to the United States, and is expected to provide both cost savings and increase in gross margin.

Latest news about Petros Pharmaceuticals

Petros, Lemonaid Health Collaborate to Expand Stendra Availability	Apr. 23	MT
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process	Apr. 16	MT
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)	Apr. 16	CI
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status	Apr. 02	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider	Feb. 14	CI
Top Premarket Gainers	Jan. 30	MT
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study	Jan. 17	CI
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status	Dec. 12	CI
Maxim Initiates Petros Pharma at Buy Rating With $4 Price Target	Dec. 08	MT
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider	Dec. 05	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)	23-10-30	CI
Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA	23-10-19	CI
Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label	23-10-04	CI
Top Premarket Decliners	23-10-04	MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Petros Pharmaceuticals Secures $15 Million Private Placement Financing	23-07-14	MT
Petros Pharmaceuticals, Inc. announced that it has received $15 million in funding	23-07-12	CI
Petros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Top Premarket Decliners	23-04-17	MT
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected	23-04-14	MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports	23-04-14	MT
Top Premarket Gainers	23-04-14	MT
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI

Chart Petros Pharmaceuticals

Duration

Period

More charts

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics with a range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The Company is also focused on identifying, developing, acquiring, and commercializing therapeutics for men's health issues, including, erectile dysfunction (ED), endothelial dysfunction, psychosexual and psychosocial ailments, peyronie's disease, hormone health, and substance use disorders. The Company also markets its own line of ED products in the form of vacuum erection device (VED) products through its subsidiaries, Timm Medical, Inc. In addition, its ED products, the Company is focused on identifying and developing other pharmaceuticals to advance men's health, which is H100, which is the topical formulation candidate for the treatment of acute peyronie's disease.

Sector

More about the company